259183-32-9

Basic information

• Product Name: Acetamide, 2-[4-[[5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- 1H-benzimidazol-1-yl]sulfonyl]phenoxy]-
• CAS NO: 259183-32-9
• Molecular Formula: C25H26N4O7S2
• Molecular Weight: 558.636
• Mol File: 259183-32-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Acetamide, 2-[4-[[5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- 1H-benzimidazol-1-yl]sulfonyl]phenoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, 2-[4-[[5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- 1H-benzimidazol-1-yl]sulfonyl]phenoxy]-(259183-32-9)
• EPA Substance Registry System: Acetamide, 2-[4-[[5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- 1H-benzimidazol-1-yl]sulfonyl]phenoxy]-(259183-32-9)

Safety Data

• Hazardous Substances Data: 259183-32-9(Hazardous Substances Data)

Upstream product

• 69986-21-6 2-[p-(chlorosulfonyl)phenoxy]acetamide 
• 73590-58-6 omeprazole 
• 843615-54-3 2-[4-({5-methoxy-2-[(4-methoxy-3,5-dimethyl(2-pyridyl))methylthio]benzimidazolyl}sulfonyl)phenoxy]acetamide 

Relevant articles and documents

1-arylsulfonyl-2-(Pyridylmethylsulfinyl) benzimidazoles as new proton pump inhibitor prodrugs

New arylsulfonyl proton pump inhibitor (PPI) prodrug forms were synthesized. These prodrugs provided longer residence time of an effective PPI plasma concentration, resulting in better gastric acid inhibition.

Prodrugs of proton pump inhibitors

Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under physiological conditions to provide the proton pump inhibitors with a half life measurable in hours, and are capable of providing sustained plasma concentrations of the proton pump inhibitor drugs for longer time than presently used drugs. The generation of the proton pump inhibitor drugs from the prodrugs of the invention under physiological conditions allows for more effective treatment of several diseases and conditions caused by gastric acid secretion.